SAN DIEGO, May 10, 2022 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms, today announced that it will present two posters at the 19th Meeting of the Society for Natural Immunity (NK2022), taking place May 14 – 17, 2022 at the Hyatt Coconut Point in Bonita Springs, Florida. Shoreline will present two posters demonstrating its novel methodologies to produce iNK cells.
“We are pleased to present our proprietary CAR-NK and iNK methodologies at the NK2022 meeting, which adds to Shoreline’s growing contribution to the advancement of the cellular immunotherapy field,” said Robert Hollingsworth, Ph.D., CSO of Shoreline. “We believe we can improve upon existing CAR-NK and CAR-T therapies with our novel approach, and we look forward to building our pipeline of iPSC-derived programs and preparing for our next steps as a clinical company.”
Details of the poster presentations are below:
Title: “Development of an iPSC-derived NK cell screening platform for discovery of NK cell optimized Chimeric Antigen Receptors (CARs) for next-generation CAR-NK cell immunotherapies” Poster Number: 56, Poster Session I Date: Sunday, May 15, 2022
Title:“A novel method to produce clinical scale induced pluripotent stem cell-derived natural killer (iPSC-NK) cells with improved anti-tumor activity for next-generation allogenic cell therapies” Poster Number: 185, Poster Session II Date: Monday, May 16, 2022
For more information, please visit the NK2022 meeting website at NK2022.
About Shoreline Biosciences
Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells, or iPSCs, utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms. The company’s platforms are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of specific effector cell types, including iNK cells and iMACs as allogeneic “off-the-shelf” cellular immunotherapies designed for durability, scalability, safety and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company. Shoreline Biosciences is headquartered in San Diego, CA.
SAN DIEGO, April 12, 2022 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms, today announced the presentation of data at the American Association for Cancer Research (AACR) annual meeting in New Orleans, LA, taking place from April 8-13, 2022. Shoreline presented two posters demonstrating its novel methodologies to produce clinical scale iPSC-derived iNK cells.
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, “off-the-shelf” production. Shoreline’s methodology supports the production of phenotypically and functionally mature iNK cells from both wildtype and genetically engineered iPSCs. In particular, the generation of iPSC-derived NK cells bearing a knock-out of the gene encoding cytokine-inducible SH2-containing protein (CISH) was described at the AACR meeting. Shoreline’s CISH-KO iNK cells have demonstrated improved in vivo anti-tumor activity, persistence, metabolic fitness, and resistance to cell exhaustion.
To improve the targeting and potency of its iNK cells, Shoreline has also developed a proprietary Chimeric Antigen Receptor (CAR) screening platform to identify CARs that function optimally in NK cells. Compared to CARs developed for T cells and transferred into NK cells, Shoreline’s NK-optimized CARs yield significantly increased tumor killing activity.
“The presentations at AACR 2022 on our CISH-KO iNK cells and natural killer-optimized CARs demonstrate our sophisticated expertise in iPSC differentiation, gene editing, and CAR-NK development. This technology is being applied to multiple therapeutic programs, and along with our partnerships with Kite and BeiGene, serves as the basis for our strong pipeline of novel cancer therapies,” said Robert Hollingsworth, Ph.D., CSO of Shoreline. “Our differentiated approaches improve upon existing CAR-NK and CAR-T technologies, and we are continuing to optimize our cell therapies for potency, durability, and safety. We are excited to advance these therapies into clinical testing and eventually provide important new options for cancer patients.”
Details of the Shoreline posters are below:
Title: “Development of an iPSC-derived NK cell screening platform for discovery of NK cell optimized Chimeric Antigen Receptors (CARs) for next-generation CAR-NK cell immunotherapies” Session Title: Adoptive Cell Therapy 1 Session Date and Time: Sunday April 10, 2022 1:30 PM – 5:00 PM Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 36
Title:“A novel method to produce clinical scale induced pluripotent stem cell-derived natural killer (iPSC-NK) cells with improved anti-tumor activity for next-generation allogenic cell therapies” Abstract Number: 4319 Session Title: Stem Cells and Regulatory Pathways in Cancer Session Date and Time: Tuesday April 12, 2022 1:30 PM – 5:00 PM Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 12
Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells, or iPSCs, utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms. The company’s platforms are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of specific effector cell types, including iNK cells and iMACsas allogeneic “off-the-shelf” cellular immunotherapies designed for durability, scalability, safety and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company. Shoreline Biosciences is headquartered in San Diego, CA.
San Diego, Calif., March 28, 2022 – Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage platforms (iMACs), today announced that management will deliver an oral presentation at the Innate Killer Summit 2022 meeting taking place in San Diego, CA from March 30-April 1, 2022.
Details of the Shoreline oral presentation are as follows:
Title:“Extending the Proliferative Capacity & Persistence of NK Cells In Vivo”
Presenter: William Sandborn, MD, Co-Founder and Chief Medical Officer of Shoreline
Date and Time: Thursday, March 31, 2022, 11:00 AM PT
Location: Sheraton San Diego Hotel & Marina, San Diego, CA
The Innate Killer Summit is the oldest, largest, and most comprehensive industry-focused meeting, spanning discovery to phase development. The meeting cultivates innovative collaborations and forward-thinking discussions amongst scientists and business experts, all committed to advancing innate cell therapies.
Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and iPSC-derived macrophage platforms (iMACs). The company’s iNK and iMACs platforms are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of specific effector cell types, including NK cells and macrophages as allogeneic “off-the-shelf” cellular immunotherapies designed for durability, scalability, safety and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company. Shoreline Biosciences is headquartered in San Diego, CA.
SAN DIEGO, March 15, 2022 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage platforms (iMACs), today announced the appointment of Robert Hollingsworth, Ph.D., as its Chief Scientific Officer.
“I am thrilled to welcome Bob as Chief Scientific Officer of Shoreline. Bob is a proven R&D oncology leader with more than twenty-five years of experience in both small and large organizations and has advanced multiple programs to clinical development across a broad range of therapeutic modalities,” said Kleanthis G. Xanthopoulos, Ph.D., Chairman and CEO. “We look forward to Bob driving innovation across our iNK and iMACs platforms through his deep understanding of cancer biology and cell-based immunotherapies and helping us further enhance our technologies and advance our pipeline toward the clinic.”
Dr. Hollingsworth joins Shoreline from Pfizer, Inc., where he served as Chief Scientific Officer and Vice President of Cancer Vaccines and Immunotherapeutics. While at Pfizer, Dr. Hollingsworth led a large oncology research team who successfully advanced five programs into clinical development and implemented several innovative new therapeutic approaches. Prior to Pfizer, he was Senior Director, Oncology Research at MedImmune where he led and advanced a large portfolio of more than twenty programs, including CAR-T programs partnered with Juno Therapeutics and the National Cancer Institute, and contributed to the approval of durvalumab (IMFINZI®). Before that, he held several R&D positions of increasing responsibility at GlaxoSmithKline (GSK), Pharmacia and Upjohn.
Dr. Hollingsworth is a decorated scientist with several prestigious awards and honors including the GSK Great Science Award, given to the top R&D scientist each year, and a Research Excellence Team Award at Pfizer for developing an innovative new therapy. Dr. Hollingsworth has published over 50 papers, co-authored over 200 abstracts presented at scientific meetings, and is a co-inventor on over 15 awarded patents. He received a B.A. in Biology and Physics from the University of California, Berkeley, a Ph.D. in Biochemistry, Biophysics, and Genetics from the University of Colorado, and was an American Cancer Society Postdoctoral Fellow at the University of Texas Institute of Biotechnology in San Antonio, Texas.
“I am very excited to join Shoreline at a time when the company is starting to demonstrate the potential of its iNK and iMACs technology platforms and is preparing for its next steps as a clinical-stage company,” added Dr. Hollingsworth. “I believe that Shoreline is positioned to be a category leader that will disrupt the cell immunotherapy field, and I look forward to creating meaningful new therapies to significantly improve the lives of patients with cancer.”
About Shoreline Biosciences
Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and iPSC-derived macrophage platforms (iMACs). The company’s iNK and iMACs platforms are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of specific effector cell types, including NK cells and macrophages as allogeneic “off-the-shelf” cellular immunotherapies designed for durability, scalability, safety and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company. Shoreline Biosciences is headquartered in San Diego, CA.
San Diego, Calif., March 9, 2022 – Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (NK) cell and macrophage platforms, today announced that two of its abstracts have been accepted for presentation at the American Association for Cancer Research (AACR) annual meeting taking place April 8-13, 2022 in New Orleans, LA.
“We’re thrilled to present data on Shoreline’s innovative screening platform and methodology to discover iPSC-derived cell therapies at AACR 2022,” said Kleanthis G. Xanthopoulos, Ph.D., Chairman and CEO. “This is the first time we are showcasing our science at such an important scientific meeting, and we look forward to contributing to the advancement of the cell therapy space through our differentiated approach.”
Details of the poster presentations are below:
Title:“A novel method to produce clinical scale induced pluripotent stem cell-derived natural killer (iPSC-NK) cells with improved anti-tumor activity for next-generation allogenic cell therapies”
Abstract Number: 4319
Session Title: Stem Cells and Regulatory Pathways in Cancer
Session Date and Time: Tuesday April 12, 2022 1:30 PM – 5:00 PM
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 12
Title: “Development of an iPSC-derived NK cell screening platform for discovery of NK cell optimized Chimeric Antigen Receptors (CARs) for next-generation CAR-NK cell immunotherapies”
Session Title: Adoptive Cell Therapy 1
Session Date and Time: Sunday April 10, 2022 1:30 PM – 5:00 PM
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 36
Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (NK) cell and iPSC-derived macrophage platforms. The company’s platforms are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of specific effector cell types, including NK cells and macrophages as allogeneic “off-the-shelf” cellular immunotherapies designed for durability, scalability, safety and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company. Shoreline Biosciences is headquartered in San Diego, CA.
San Diego, Calif., February 15, 2022 – Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing our proprietary iPSC-derived natural killer (NK) cell and macrophage platforms, today announced the appointments of Lisa Melia as Vice President, Clinical Operations, Pinky Doshi as Vice President, Regulatory Affairs, and Paschalis Sideras as Vice President, Discovery Immunobiology.
“We’re thrilled to welcome Lisa, Pinky and Paschalis to Shoreline, who bring decades of experience building and leading clinical, regulatory and discovery teams for multiple successful immunotherapy products and programs,” said Kleanthis G. Xanthopoulos, Ph.D., Chairman and CEO. “We look forward to leveraging their collective backgrounds as we advance our robust pipeline of cellular immunotherapies.”
New Appointment Bios
Lisa Ann Melia is a respected clinical research professional with extensive experience in the planning and execution of clinical studies from Phase 1 through Phase 3, in the US, Europe, Asia and Latin America. Prior to joining Shoreline, Ms. Melia served as Vice President, Clinical Operations at Indaptus Therapeutics, where she was responsible for all clinical activities related to a Phase 1 first-in-human study in patients with advanced solid tumors. Prior to that, she was Vice President, Clinical Operations for MEI Pharma, Regulus Therapeutics, and the California Institute for Biomedical Research (Calibr). Previously, she held clinical positions at Pfizer Worldwide R&D, Icon Clinical Research, Ceregene and Acadia Pharmaceuticals. Ms. Melia began her industry career with Boehringer Ingelheim Pharmaceuticals. Ms. Melia holds an MA in Psychology from the University of Tennessee at Knoxville and a BA in Psychology from Trinity University.
Pinky Doshi brings to Shoreline more than two decades of global regulatory experience within the pharmaceutical industry. Prior to joining Shoreline, Ms. Doshi served as Senior Director, Regulatory at Bristol Myers Squibb, BMS, (formerly Celgene prior to 2019), Cell Therapy Franchise where she was the global regulatory lead on theAbecmaTM program and was the regional US lead providing strategic guidance for the first BCMA CAR T for relapsed or refractory multiple myeloma. In addition, she served as the global regulatory lead for early and late-stage solid tumor oncology programs. Prior to BMS, Ms. Doshi served in several regulatory positions across multiple therapeutic areas in early and late-stage therapeutics at Hoffmann-La Roche, Schering Plough Research Institute, and Johnson & Johnson Pharmaceutical Research & Development. Prior to that, Ms. Doshi held regulatory positions at Halsey Drug Company, Quest International, and TAP Pharmaceuticals. Ms. Doshi holds a Bachelor of Science, Cell and Structural Biology from the University of Illinois and a Master of Science, Biotechnology from Northwestern University.
Paschalis Sideras brings more than three decades of global experience in immunology research within both academia and the pharmaceutical industry. Dr. Sideras joins the company from the Academy of Athens where he served as Director of the Centre for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation. Before that, he served in roles of increasing responsibility at AstraZeneca in the R&D team in Lund, Sweden. Prior to AstraZeneca, Dr. Sideras served in several academic roles including Assistant Professor of Cell and Molecular Biology and Visiting Scientist where he oversaw teams of graduate students and post-doctoral fellows across many scientific disciplines. He holds a Dr. Med. Sci. in Immunology, from the Karolinska Institute in Stockholm, Sweden and a Docent in Molecular Immunology, from Umeå University in Umeå, Sweden.
About Shoreline Biosciences
Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells, or iPSCs, utilizing our proprietary iPSC-derived natural killer, or NK, cell and iPSC-derived macrophage platforms. The company’s platforms are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of specific effector cell types, including NK cells and macrophages as allogeneic “off-the-shelf” cellular immunotherapies designed for durability, scalability, safety and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company. Shoreline Biosciences is headquartered in San Diego, CA.
In another record year for biopharma fundraisings, more money than ever pulsed through the industry. The volume and value of pharma IPOs and venture capital financings are at their highest levels. Private financings for 2021 easily outdistanced those from 2020, much of it powered by SPACs. Where is it all going in 2022? Two experts joined BioWorld to share their thoughts. Kleanthis Xanthopoulos is a co-founder and executive chairman of Shoreline Biosciences. For more than 20 years he’s been an executive, company founder, CEO, investor and board member in biopharma research. Also joining the discussion was Joe Hernandez, CEO and executive chairman of Blue Water Vaccines, who founded or led eight health care and pharmaceuticals companies.
In another record year for biopharma fundraisings, more money than ever pulsed through the industry. The volume and value of pharma IPOs and venture capital financings are at their highest levels. Private financings for 2021 easily outdistanced those from 2020, much of it powered by SPACs. Where is it all going in 2022? Two experts joined BioWorld to share their thoughts. Kleanthis Xanthopoulos is a co-founder and executive chairman of Shoreline Biosciences. For more than 20 years he’s been an executive, company founder, CEO, investor and board member in biopharma research. Also joining the discussion was Joe Hernandez, CEO and executive chairman of Blue Water Vaccines, who founded or led eight health care and pharmaceuticals companies.
Natural killer cells, the body’s first line of defence against emerging cancers, could be engineered into powerful, off-the-shelf cancer therapies.
Natural killer (NK) cells are part of the innate immune system, the body’s first line of defense against cancer. Credit: Alpha Tauri 3D Graphics/Shutterstock
Billions of highly trained killers are flowing through your fingers right now. They patrol your internal organs, guard the tissues under your skin against invaders, and wipe out virus-infected cells. They remain vigilant against cancer — recognising and destroying the early signs of tumours before they can gain a foothold.
These tiny terminators, called natural killer (NK) cells, are one of the body’s strongest defences against illness and disease — and yet the hundreds of billions of NK cells in our own bodies sometimes aren’t enough. Now researchers want to engineer NK cells as reinforcements, and store ranks of those reinforcement NK cells to be called up and deployed as needed (see ‘Engineering a tumor killer’). They want to make these engineered NK cells available to cancer patients and others as living drugs, without having to personalize them for each patient, as is the case with other cell therapies.
“We want to make cells that work like drugs,” says Dan Kaufman, a professor of regenerative medicine at the UC San Diego School of Medicine and co-founder and chief scientific officer of Shoreline Biosciences. “When you take a blood pressure medicine or a cholesterol medicine, everybody gets the same thing. You know the doses and it’s standardized. Using these engineered NK cells, we can do that. We can make hundreds, or potentially thousands, of doses of these NK cells all the same and use them as off-the-shelf therapies.”
Immunotherapy strategies
The idea builds on the success of so-called CAR-T cells, which are used as immunotherapies against several types of cancer. These cell-based therapies are based on a different immune component, called T cells. By collecting a patient’s T cells, engineering them to make them more potent, and then infusing them into the body, scientists can supercharge the cancer-fighting ability of the patient’s immune system. Five CAR-T cell therapies have been approved by the US Food and Drug Administration against several blood cancers.
NK cell immunotherapy has not yet reached that stage. “The natural killer cell approach in terms of cancer immunotherapy is newer, and rapidly gaining recognition,” says Hans-Gustaf Ljunggren, who works on cell therapies at the Karolinska Institute in Stockholm, Sweden. “There are numerous clinical trials going on with various natural killer cell-based products.”
Although there are clinical trials of NK cells in progress for multiple different blood cancers, nothing has been approved yet.1 “But it’s not unlikely that we will see such products within the coming five years,” Ljunggren says.
To help translate his own research on NK cells into commercial therapies, Kaufman co-founded Shoreline Biosciences. The company raised $43 million in financing earlier this year and entered into two partnerships with two immunotherapy companies, Kite Pharma and BeiGene, to develop novel cell therapies. The company recently concluded another round of financing that raised an additional $140 million.
One of the goals of NK cell therapies is to make them significantly cheaper than CAR-T cell treatments, Kaufman says. “It’s very expensive to take out the T-cells, engineer them and give them back to each individual patient. It costs roughly half a million dollars to make the cells for one patient.” The process also takes several weeks.
Innate fighters
NK cell therapies can be made more quickly and at lower cost because NK cells function in a different way. T cells are part of the adaptive immune system, the body’s second line of defence against both viral infections and cancer. They are primed to recognise specific foreign proteins on the surface of a patient’s own cells. Because T cells from one person recognize healthy cells from other people as foreign, only a patient’s own T cells can be used as a therapy — hence the need to remove and engineer them at such cost.
NK cells work in the frontline innate immune response, in which they patrol the body and attack any cells that are not recognised as part of the host tissue. This more indiscriminate approach means that NK cells therapies can be sourced elsewhere and more easily given as a standard treatment to many different patients.
“You can essentially establish banks of hopefully potent NK cells that could then be distributed globally to be used for treatment of cancers,” Ljunggren explains.
Because they do not need to be taken from a specific patient, Kaufman began developing NK cells for potential therapies from induced pluripotent stem (iPS) cells — skin or blood cells that have been reprogrammed back into an immature state that lets them develop into any other type of cell.
“Dan is one of the pioneers in the generation of the IPS derived NK cells,” Ljunggren says. “And now IPS NK cells have become a very interesting and relatively new aspect of cell therapies.”
Genetic manipulation
Besides being more universal, deriving the NK therapies from pluripotent stem cells brings another advantage. Manipulating the genome of the stem cells before they are converted to NK cells offers a reliable way to introduce genetic changes that could improve potential therapies.
When faced with attacking NK cells, cancer cell don’t sit idly by. “We know there are ways that the tumour cells can sort of evolve to avoid the immune system,” Kaufman says.
Kaufman’s group has countered by engineering NK cells into better cancer fighters. “We can engineer these NK cells to provide additional mechanisms or more activated cells that seem to be able to overcome those barriers.”
They have done this by knocking out a gene called CISH, which is involved in regulating cell-signalling molecules called cytokines. NK cells without the CISH gene are more sensitive to the cytokine IL-15, which leads to greater cell proliferation. As a result, the cells live longer inside the body and show enhanced anti-tumour activity.2
Trials ahead
Several challenges remain. Like CAR-T cells, NK cell therapies seem less effective against solid tumours. And because they are not based on host cells, the engineered NK cells can trigger an immune response, which tries to reject them. Researchers deal with that at present with doses of chemotherapy to suppress the host immune system. But Kaufman says they are also working on a new type of “stealth” NK cell that can evade host immunity.
“Can you also engineer these cells to avoid that immune response? That’s a challenge for later,” he says.
Shoreline has completed preclinical testing on a potential NK cell therapy for acute myeloid leukaemia. The company is now working on ways to manufacture the cells to the required clinical grade, and to test them for safety. That work is on track, Kaufman says, and trials will begin soon.
Explore the anticancer potential of engineered natural killer cells here.
SAN DIEGO, Nov. 23, 2021 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and Macrophage cellular immunotherapies, today announced that company management will present and conduct one-on-one meetings at the Piper Sandler 33rd Annual Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference:
Piper Sandler 33rd Annual Healthcare Conference
Monday, November 29, 2021, Private Company Day
Pre-recorded presentation will be available on Monday, November 22, 2021 at 10 AM ET to conference attendees
4th Annual Evercore ISI HealthCONx Conference
Tuesday, November 30, 2021, fireside chat at 12:10 PM ET
About Shoreline Biosciences
Shoreline is dedicated to creating next-generation cellular immunotherapies for cancer that overcome the limitations of current cell therapy products. Shoreline is advancing a pipeline of natural killer cell and macrophage-cell therapies into the clinic. Shoreline’s clinical candidates are derived from the company’s deep expertise in iPSC differentiation methods and genetic reprogramming of disease relevant pathways. Shoreline has strategic partnerships with Kite, a Gilead Company, and BeiGene, a global biotechnology company, Contract Development and Manufacturing Organization partnerships with well-established organizations, and is supported by high-quality investors. Shoreline Biosciences is headquartered in San Diego, CA.
